In our view, Global Wholehealth Partners Corp. (OTC - GWHP – NR) is positioned to emerge as the next major COVID-19 diagnostics company.

Following the close of strategic acquisitions, emerging CBD Pharma company PAO Group, Inc. (OTC - PAOG - NR) is a company to watch closely as it could enjoy a major rise in value as it completes key milestones.

See why PetVivo (OTC - PETV) has the best valuation and upside in the industry.

Given the huge runs electric vehicle (EV) stocks have made of late we elected to draft an EV industry snapshot and highlight the space and key companies, including low price alternatives to Tesla (NASDAQ – TSLA) such as Alternet Systems (OTC – ALYI – Spec Buy)..

PETV is well-positioned to emerge as the standard of care for the treatment of osteoarthritis in dogs and horses, an unmet need representing an estimated $3.2B market.

CBD Life Sciences, Inc. (OTC – CBDL) is not your typical CBD company. With a robust online business, brick and mortar location, combined with a diverse offering in key, in-demand categories, CBDL is poised to continue to generate strong sales growth ahead.

In a matter of weeks, China Xiangtai Food Corp., Ltd (NASDAQ – PLIN) has made an acquisition and entered into a JV—both steps prompt major forecast increases, with a price target upgrade under review.

While the industry zigs (or contracts) American Energy Partners, Inc. (OTC – AEPT) zags (grows like crazy). AEPT is enjoying record sales growth and solid profits. The whole complexion and profile, are changing and management confirmed that new M&A could be on the horizon which could take the valuation to a new level.

Nascent Biotech (OTC – NBIO) is slated to release in vitro studies that demonstrate its lead candidate may have an impact in treatment of coronaviruses as Pritumumab may have the ability to interfere with the virus’ binding to target cells, thus possibly eliminating deadly effects.

Data443 Risk Mitigation, Inc. (OTC - ATDS) is oversold, misunderstood, offers great value and significant upside potential, per our new 6 month price target